Pulsed field ablation (PFA) technology made some advances with 12-month results for the Globe Pulsed Field System in ...

Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, today announced the initiation of the ...

Abbott has reported new data from its Volt CE Mark Study in individuals treated with PFA therapy using the Volt PFA System ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive clinical outcomes from two studies in atrial fibrillation (AFib) patients treated with the Affera™ family ...

Emerging pulsed field ablation systems had their moments in the spotlight at the annual meeting of the Heart Rhythm Society ...

Omny-IRE data demonstrated the investigational OMNYPULSETM Platform achieved 100% acute success and 84.5% pulmonary vein isolation (PVI) durabilit ...

One-year clinical trial data for the next-generation, investigational, Sphere-360TM single-shot PFA catheter show impressive safety, perf ...

Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of ...

Boston Scientific Corporation today announced positive 12-month primary endpoint results from the second phase of the ...

Boston Scientific reports positive outcomes from the ADVANTAGE AF trial’s second phase, assessing the Farapulse and Farapoint ...

The upper pulmonary veins (PVs) are responsible for the majority of atrial fibrillation (AF) triggering foci, whereas the inferior PVs are more difficult to ablate and prone to postablation ostial ...

PFA is a newer Afib ablation modality touted as reducing the risk of damaging nearby collateral structures, compared with ...